

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 27, 2026**

OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-38242
(Commission File Number)

26-1761833
(I.R.S. Employer Identification Number)

2850 Frontier Drive
Warsaw, Indiana
(Address of principal executive offices)

46582
(Zip Code)

Registrant's telephone number, including area code: **(574) 268-6379**

Not Applicable
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00025 par value per share	KIDS	Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits	
	<u>Exhibit No.</u>	<u>Description</u>
	99.1	OrthoPediatrics Corp. Investor Presentation dated October 2026
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
		* * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OrthoPediatrics Corp.

Date: October 27, 2026

By: /s/ Daniel J. Gerritzen
Daniel J. Gerritzen,
General Counsel and Secretary



2026 Investor Presentation



 www.OrthoPediatrics.com



Disclaimer

Forward-Looking Statements

All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements speak only as of the date of this presentation. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others; We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in our quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2026, and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this presentation.

Use of Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Free cash flow, which we reconcile to "Net cash provided by (used in) operating activities" is cash flow from operations reduced by "Capital expenditures". Adjusted loss per share in this presentation represents diluted loss per share on a GAAP basis, excluding intangible asset impairment, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this presentation represents net loss, plus interest expense, net plus other expense (income), net plus income tax charge (benefit), depreciation and amortization, intangible asset impairment, stock-based compensation expense, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and the cost of minimum purchase commitments. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. The Company believes the non-GAAP measures provided in this presentation enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company's operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management's use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company's presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using these adjusted measures on a supplemental basis. The Company's definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules included contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.



OrthoPediatrics was founded on the **cause** of impacting the lives of children with orthopedic conditions


+ 1,425,000

pediatric patients treated since inception¹

- 01 Children's **unique clinical conditions**
- 02 Existing solutions are **re-purposed from adult implants**
- 03 Limited development of **new technologies**
- 04 No **specialized sales force** in Pediatric Orthopedics
- 05 Limited industry support of clinical **education**

Re-Purposed Adult Plate

Screws through growth plate



PediLoc Femur

Screws parallel to growth plate



- 01 **Product development focused** exclusively on pediatric patients
- 02 **Broadest pediatric specific portfolio** in the industry
- 03 Delivering first in market **novel surgical solutions**
- 04 Only global **commercial channel to market**
- 05 Leading provider of surgeon **clinical education**

- ✓ Enhance surgeon confidence
- ✓ Increase surgical efficiency
- ✓ Improve surgical accuracy



Innovative Technology

95+ unique pediatric systems
Consistent **cadence** of innovative product launches
Expanding suite of **enabling** technologies
Internal **R&D**, acquisitions, and partnerships



Commercial Execution

Only global sales & distribution channel
Serve **100% of top children's hospitals** in the U.S.
~**240** domestic field representatives
Sell in **over 75** countries around the world




Clinical Education

Commitment to clinical education
Leading **sponsor** of critical pediatric medical societies
>700 clinical product/education events per year
Founder of Foundation of Advancing Pediatric Orthopedics

**Consistent
YoY
Growth
Since Inception¹**

U.S. Addressable Market¹ — \$2.8B



2026 // Investor Presentation

¹ Management's Estimate as of January 2025 updates to IMS data from 2016

Competitive Dynamics

- 01 Large incumbents repurpose adult implants
- 02 Require specialized sales force
- 03 Lack of focus on pediatric conditions



01



Laser focus on high-volume Children's Hospitals that treat majority of pediatric patients

02



Provide a **broad product portfolio** uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs

03



Deploy instrument sets and provide unparalleled sales support

04




Expand addressable market through aggressive investment in **R&D** and **select M&A opportunities**

05



Train next generation of pediatric orthopedic surgeons

Current U.S. Target Market¹ — \$1.6B


2026 // Investor Presentation

¹ Management's Estimate as of January 2025 updates to IMS data from 2016

Comments

- 01 ~1,700 Fellowship Trained Pediatric Surgeons
- 02 Majority of Pediatric Centers are Teaching Hospitals
- 03 Centers Treat Most Complex Pediatric Conditions
- 04 ~80% of Pediatric Surgeons time is Non-Surgical


20 Years of Foundation Building



95+ Systems

Broadest Portfolio across:

- Trauma & Def
- Scoliosis
- Sports Med
- External Fixation
- Specialty Bracing
- Enabling Tech



Surgeon-led Innovation

- New products originate from unmet clinical needs identified by pediatric orthopedic surgeons

Building Platforms

- Focus on platform & product family development rather than isolated products

Multi-year super cycle

- Entered a multi-year product super cycle, with multiple launches expected over several years

Trauma & Deformity

3P™ Small | Mini

PNP | Retro

3P™ | Knee

PNP | SD

Pin to Bar Ex-Fix

Scoliosis

VerAxis™ Scoliosis

eLLi™

OPSB

Tractor Fix

Enabling Tech

Predictive
Planning

Entering a "Super-Cycle" of Differentiated Product Launches



Entering a "Super-Cycle" of Differentiated Product Launches



Total Revenue (\$M)

+20% CAGR



2026 // Investor Presentation

¹ Impacted by COVID

	2016	2025	CAGR
U.S. Independent Sales Consultants	90	232	11%
Instrument Set Deployments	\$7M	\$17M	10%
Unique Pediatric Systems	17	87	20%
Intl. Independent Sales Agencies	0	16	Fav



Accelerate Revenue Growth



Increase Hospital Penetration



Improve Profitability



Leverage Balance Sheet

Set Deployment Efficiencies

Reducing set deployments as a percentage of revenue while continuing to take share



¹ Boston O&P Acquisition

² Represents the midpoint of the Company's 2026 revenue guidance range of \$270.0 to \$273.0 million and expected annual set deployment

Improving ROI on Sets Deployed

01

Super Cycle Product Launches

- Products with defined clinical needs & stronger financial profile (higher ASPs and gross margins, less capital required)

02


Higher Utilization

- Market share gains and ramping in utilization of previous deployments creates leverage

03

Platform Systems

- Systems designed to utilize similar parts produces platform synergies and capital efficiencies





**Aggressive market-based
clinic expansion strategy**

18 new markets by 2027
(27 total)



**Accelerate R&D with
increasing number of YoY
launches**

Launch 4 products in 2024
and 5 in 2025



**Scale OPSB selling channel
and sales force – grow with
current portfolio of
products**

Doubling size of the sales
channel

Pace of Market Expansion



+4 markets
in 2025

+6 markets
in 2026


+8 markets
in 2027

**OPSB clinics
expected to be in 27
territories in 2027
out of 80
target territories**

	Greenfield	Acqui-Hire
Initial Investment	\$200k-\$500k	\$500K-\$1M
EBITDA Goal	Positive EBITDA by end of first full year	Positive EBITDA by end of first full year
FCF Goal	After first full year	Within first year
ROI Goal	Break even ROI by Year 3	Break even ROI by Year 5
Time to Ramp	6 months for licensure, insurance, lease, clinicians, training, etc.	Immediate licensure, insurance, location, clinicians, training etc.
IRR	40%	25%

**1-4
Clinics
per
market
expected**

U.S. Potential Target Market ¹ — \$1.0B



2026 // Investor Presentation

¹ Management's Estimate as of January 2026



**Levity Device
for Gait Assist**



**Dynamic Femur
Fracture (DF2)
Brace**

Supporting more than 20 fellowships

01 OP Hands-on sales training and support

- Annually invests 3% of sales on clinical education
- Conducts >700 product/training sessions per year

02 Market development

- Fosters early relationships with young surgeons and fellows to drive sustainable growth

03 Continuous education

- Major Sponsor of the prominent pediatric orthopedic societies





Trauma & Deformity



70% of Revenue



Scoliosis



28% of Revenue




2025 Revenue by Product Family




■ Trauma & Deformity
■ Scoliosis
■ Sports Medicine

Strong History of Y/Y Growth (\$M)



Seasonality Drives Stronger Performance in Summer Months and Holiday Periods



(\$ in Millions)

Income Statement Summary

	FY2023	FY2024	FY2025
Revenue	\$148.7	\$204.7	\$236.3
Growth %	22%	38%	15%
Gross profit	\$111.3	\$148.6	\$172.7
Margin %	75%	73%	73%
Operating expenses	\$138.0	\$183.6	\$211.9
Operating loss	(\$26.8)	(\$35.0)	(\$39.2)
Net (loss) income	(\$21.0)	(\$37.8)	(\$39.6)
EPS diluted	(\$0.92)	(\$1.64)	(\$1.69)


3Q 2025	3Q 2026
\$61.2	\$72.7
12%	19%
\$45.3	\$54.0
74%	74%
\$54.7	\$58.2
(\$9.4)	(\$4.2)
(\$11.8)	(\$5.9)
(\$0.50)	(\$0.25)

(\$ in Millions)

Adjusted EBITDA Reconciliation

	Three Months Ended September 30,	
	2025	2026
Net loss	(\$11.8)	(\$5.9)
Interest expense, net	1.8	2.6
Other expense (income), net	0.6	-
Income tax charge (benefit)	(0.1)	(0.1)
Depreciation and amortization	5.3	5.6
Intangible asset impairment	2.3	0.6
Stock-based compensation	4.3	4.4
Fair value adj. of contingent consideration	-	(0.8)
Restructuring charges	2.3	-
Tariffs	0.3	0.2
Acquisition-related costs	0.9	0.3
Minimum purchase commitment cost	0.3	-
Adjusted EBITDA	\$6.2	\$6.9

	Three Months Ended September 30,	
	2025	2026
Loss per share, diluted (GAAP)	(\$0.50)	(\$0.25)
Intangible asset impairment	0.10	0.03
Fair value adj. of contingent consideration	-	(0.03)
Tariffs	0.01	0.01
Restructuring charges	0.10	-
Acquisition-related costs	0.04	0.01
Minimum purchase commitment cost	0.01	-
Adjusted loss per share, diluted (non-GAAP)	(\$0.24)	(\$0.23)



(\$ in Millions)
As of September 30, 2026

Assets	
Cash, cash equivalents & short-term investments	\$44.9
Accounts receivable	59.5
Inventory (net)	141.9
Other current assets	6.9
Total Current Assets	253.2
PP&E (net)	47.0
Intangibles and goodwill	208.9
Total Assets	\$509.1

Liabilities	
Accounts payable	\$24.5
Debt	98.4
Accrued comp. & other liab.	42.1
Acquisition pay. & cont. consideration	4.8
Paid-in capital	637.3
Accumulated deficit (net)	(299.0)
Accumulated other comprehensive loss	1.0
Total Liabilities / Equity	\$509.1

2026 Guidance

	FY2026
Revenue	\$270.0 to \$273.0
Adjusted EBITDA	~\$25.0
Free Cash Flow	Breakeven

Assumptions

	FY2026
2026 Total Revenue Growth %	14% to 16%
Set Deployment	~\$10.0



- 01 Only diversified company focused exclusively on pediatric orthopedics
- 02 Large, underpenetrated market opportunity in pediatrics
- 03 Highly concentrated customer base with targeted commercial strategy
- 04 Broad product portfolio with innovative solutions
- 05 Only provider committed to pediatric clinical education
- 06 Dynamic, award-winning corporate culture
- 07 Proven commercial execution and attractive financial profile



